Eosinophilic Esophagitis Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access

Table of Contents

• A chronic, inflammatory disorder of the immune system in the esophagus, characterized by dysphagia, food impaction, and regurgitation
• Figure 1.1. Pathophysiology of EoE
• EoE is the most common form of EGID
• Figure 1.2. Classification of EoE
• Table 1.1 EoE and GERD are not mutually exclusive and can co-occur but have their own distinguishing features

• Disease definition
• Figure 2.1 - G6 diagnosed prevalent cases of EoE by region
• Table 2.1 - Diagnosed prevalent and drug-treated patients in the G6

• Diagnosis overview
• Figure 3.1. Diagnostic pathway for EoE patients
• Figure 3.2. Gastroenterologist-Reported Misdiagnosis and Delayed Diagnosis Among EoE Patients
• Dietary therapy, PPIs and corticosteroids are the current standards of care
• Treatment overview
• Figure 3.3. Treatment goals for EoE
• Figure 3.4. Current Treatment Patient Share
• Treatment flow for EoE
• Figure 3.5. Treatment algorithm for EoE
• Physicians are satisfied with the efficacy of current treatments for EoE
• Figure 3.6. Gastroenterologist rating (n=25) of current therapy effectiveness in EoE
• Figure 3.7. Gastroenterologist-reported percentage of EoE patients who are refractory to current pharmacologic treatment options
• Existing treatments work well but convenience could be improved for chronic use
• Gastroenterologists’ opinions on current treatments
• Dupilumab is the first and only FDA-approved drug for EoE
• Figure 3.8. Phase 3 results for Regeneron/Sanofi’s dupilumab in EoE
• Dupilumab is viewed favorably by physicians
• Figure 3.9. Dupixent’s advantages observed in clinical practice
• Figure 3.10. Treatment dynamics observed in clinical practice
• Key treatment dynamics that shape disease management and drug use in EoE
• Table 3.1 Must-know EoE treatment dynamics
• Figure 3.11. Percentage of drug-treated patients surveyed gastroenterologist estimate would be eligible for novel classes of EoE therapy
• The EoE market may see significant shifts over the next decade
• Figure 3.12. Important dynamics of EoE market evolution

• Overview
• Figure 4.1 - Top unmet needs in EoE
• Figure 4.2 - Physician-reported unmet needs in EoE
• Two groups of EoE patients exist whose needs can be met by novel therapeutics
• Figure 4.3 - High need patient types in EoE
• Figure 4.4. Percentage of gastroenterologists who see this as a barrier to receiving drug therapay
• The need for new EoE treatments is moderate compared to other Gi/allergic conditions
• Figure 4.5 - U.S. gastroenterologists rating of the need for new treatments in gastrointestinal and allergic conditions

• Overview
• Figure 5.1. Number of emerging therapies addressing unmet needs in EoE
• Pipeline for EoE has many late-phase products primed for launch
• Table 5.1. Comparison of ongoing trials in EoE
• The earlier phase pipeline for EoE is not as active as the late-phase pipeline
• Table 5.1. Comparison of ongoing trials in EoE (continued)
• Late-phase pipeline
• Figure 5.2. Percentage of gastroenterologists who rated the following emerging therapies as “promising”

• Overview
• Table 6.1 - Current therapy pricing
• Table 6.2 - Typical commercial payer coverage of Rituxan and Dupixent (e.g., United Healthcare, Aetna, BlueCross BlueShield, Cigna)
• Key market access dynamics that will continue to shape treatment use
• Figure 6.1. - EoE patients by insurance type
• Figure 6.2. - Gastroenterologist-reported key barriers to drug therapy for EoE patients
• Figure 6.3. Dupixent montjly copay payments of Medicare and commercially-insured patients

• Primary market research approach
• Epidemiology methodology

Samples

Companies Mentioned

• Regeneron Pharmaceuticals
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb
• Ellodi Pharmaceuticals
• EsoCap
• Pfizer
• Dr. Falk Pharma
• Revolo Biotherapeutics
• Amzell Pharma
• EMS